Skip to main content
OpenTrials
Completed

NCT Number: NCT04264312

Baseline Investigation of Chronic Hepatitis B Viruses Infections: Who is Eligible for Treated Criteria

Through two-stage stratified cluster sampling, investigators studied the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infection-related liver disease population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis B Blood-Borne Infections Communicable Diseases DNA Virus Infections Digestive System Diseases Hepadnaviridae Infections Hepatitis Hepatitis, Viral, Human Infections Liver Diseases Virus Diseases

Age range

25 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chaoyang District Center for Disease Control and Prevention, Beijing, Beijing Municipality, China

Loading trial locations.

About this study

Hepatitis B virus (HBV) infection is a major public health problem worldwide. China has the world's largest burden of HBV infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030. While, the antiviral treatment rate and the main factors affecting the antiviral treatment in community chronic HBV infections is still unknown. In response to the above situation, Sampling applied a two-stage stratified cluster sampling design in 16 Districts and 331 Townships. Investigators wanted to know the one who is eligible for treated criteria based on community in 25 and over years old in Beijing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • older than 25 years old;
  • Residents with medical insurance coverage lived in Beijing more than 6 months .

Exclusion criteria

  • Persons with pacemakers;
  • Pregnant women;
  • Persons with ascites;
  • The one whose wound was not cured at the right upper abdomen

Treatment and study plan

Primary outcomes

  1. HBsAg positive rate

    Time frame: Baseline

    Complete HBsAg tests for more than 60,000 people over the age of 25 in Beijing

  2. Average rate of chronic hepatitis B accepting antiviral treatment

    Time frame: Baseline

    The one who is eligible for HBV treated criteria based on community in 25 and over years old in Beijing.

Sponsors and collaborators

Lead sponsor

Wu Jiang

Other Gov

Registry information

Official study title

Beijing Center for Disease Prevention and Control

Important dates

Study start
2017
Primary completion
2019
Study completion
2020
First posted
Feb 11, 2020
Registry last updated
Feb 11, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.